Planmeca has announced a simpler process for ordering SomnoDent oral appliances from SomnoMed using the Planmeca Emerald intraoral scanners and the Planmeca Romexis Cloud service.
SomnoMed manufactures the world’s leading OAT (open airway therapy) oral appliances for sleep apnea treatment under the SomnoDent brand. By establishing a seamlessly integrated workflow for ordering SomnoDent oral appliances directly from the Planmeca Romexis software, Planmeca extends the range of solutions available for Planmeca Emerald users for sleep apnea treatments.
The Planmeca Emerald intraoral scanners and the Romexis software are now integrated into SomnoMed’s sleep apnea device manufacturing workflow. The workflow only includes three easy steps:
- Scan a patient’s upper and lower teeth. Place the SomGauge instrument, which is used to construct accurate and reliable bite records, in the patient’s mouth when scanning the bite
- Fill-in the digital SomnoMed Order Sheet and import it into the Romexis software
- Send the filled-in order sheet and the patient’s intraoral scans scanned in the SomGauge bite position to your local SomnoMed laboratory via the Planmeca Romexis Cloud service
“Working with SomnoMed has been very smooth as we have together strived to find the best possible workflow for our shared customers. Through this global collaboration, we are looking forward to expanding the range of oral appliances that are manufactured based on the Planmeca Emerald intraoral scanner data even further,” said Ville Salonen, Planmeca’s product line and business development manager for orthodontics and CMF surgery.
“SomnoMed is dedicated to a treatment-focused and technology-driven service offering. The SomnoDent and Planmeca Emerald integration offers dental professionals a high-quality and seamless digital workflow process to decrease costs and increase value, making it easy to expand their dental sleep treatment offering. This workflow automates the back-office operations, minimises potential errors and ensures the delivery of the mandibular advancement devices (MAD) in the fastest and most accurate way possible,” explained Frantz Jaeger, SomnoMed’s director for operations and financial control.